<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837093</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180274</org_study_id>
    <secondary_id>2018-004123-37</secondary_id>
    <secondary_id>MEDAECNAT-2018-11-0048</secondary_id>
    <secondary_id>2-17-33</secondary_id>
    <nct_id>NCT03837093</nct_id>
  </id_info>
  <brief_title>Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers</brief_title>
  <acronym>HEALTHIL-2</acronym>
  <official_title>A Study of the Dose-response Relationship of Low-dose IL-2 to the Kinetics of Regulatory T-cell Response in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the dose-response relationship of
      ILT-101 to blood Tregs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the healthy physiological state, there is homeostasis between regulatory T cells (Tregs)
      and effector T cells (Teffs) which is deregulated in autoimmune diseases (AID).

      The existence of an AID indicates a lack of Tregs. Our team has discovered that low-dose
      interleukin-2 (ld-IL2) activates and specifically increases Tregs in humans and thus may
      improve AID. Exploiting this potential requires i) to better target the dose with the best
      benefit / risk ratio and also ii) to better understand the mechanism of action of this
      molecule through clinical trials of ld-IL2 in progress, including in type 1 diabetes,
      multiple sclerosis and systemic lupus erythematosus. During these clinical trials, a very
      thorough immunological follow-up is carried out in order to discover biomarkers of treatment
      efficacy. Exploitation of these results will benefit both the cross-analysis of the effects
      of IL-2 in these 3 diseases with distinct pathophysiologies, but also very importantly a
      comparison with the effects of ld-IL2 at the healthy volunteer. These analyzes should make it
      possible to define the most effective dose of IL-2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">March 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of Tregs(in (expressed in % of CD4 and total)</measure>
    <time_frame>from Day 1 to Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC corresponding to the évolution of residual values of tregs/CD4+</measure>
    <time_frame>Day 5 to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>numbers of different circulating immune populations</measure>
    <time_frame>baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of serum cytokine(pg)</measure>
    <time_frame>from baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of serum chemokine</measure>
    <time_frame>from baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composition of the intestinal microbiota</measure>
    <time_frame>from baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events, anti IL-2 autoantibodies</measure>
    <time_frame>from baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>levels of serum anti-IL-2 autoantibodies</measure>
    <time_frame>from baseline to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ILT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ILT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ILT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ILT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dose E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ILT-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ILT101</intervention_name>
    <description>Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks</description>
    <arm_group_label>dose A</arm_group_label>
    <arm_group_label>dose B</arm_group_label>
    <arm_group_label>dose C</arm_group_label>
    <arm_group_label>dose D</arm_group_label>
    <arm_group_label>dose E</arm_group_label>
    <other_name>low-dose IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Without any chronic diseases diagnosed (including allergies);

          -  Effective contraception&gt; 2 weeks before the first administration of the experimental
             drug or its placebo and β-hCG negative at the verification of the selection criteria;

          -  Affiliated to a social security system;

          -  Free, informed and written consent, signed by the subject and the investigator, before
             any action required by the research.

          -  Not taking any treatment

        Exclusion Criteria:

          -  Subject in a period of exclusion of participation in other biomedical research;

          -  Participation in another research ≤ 1 month and during the study except for research
             Transimmunom (Non-interventional research involving the human person);

          -  known antecedents of autoimmune diseases;

          -  Hypersensitivity to any of the excipients of the investigational drug (mannitol,
             sodium laurilsulfate, monosodium phosphate dihydrate, disodium phosphate dihydrate);

          -  Evolutionary infection requiring treatment;

          -  Viral infection and benign infection less than 2 months old;

          -  Venous capital not allowing blood samples;

          -  Pregnant or lactating women;

          -  Men and women of childbearing potential without effective contraception during the
             study;

          -  Live attenuated virus vaccination in the month prior to inclusion or during the study;

          -  Surgical intervention ≤ 2 months or planned during the study;

          -  Psychiatric pathology or drug addiction that may impair ability to comply with
             protocol requirements or give informed consent;

          -  Presence or history of cancer that has not been cured for less than 5 years, except in
             situ cervical cancer, or basocellular cancer;

          -  Subject under a legal protection measure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigation Center in Biotherapy et immunology Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris l'hopital 75013 Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberta Lorenzon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Investigation Center Paris Est Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Klatzmann, Professor</last_name>
    <phone>+33(0) 1 42 16 74 61</phone>
    <email>david.klatzmann@sorbonne-universite.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta Lorenzon, MD</last_name>
    <phone>+33(0) 1 42 16 74 61</phone>
    <email>roberta.lorenzon@sorbonne-universite.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Investigation Center Paris Est Hôpital Universitaire Pitié-Salpêtrière 83 bd de l'Hôpital 75013 Paris</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low dose of IL-2</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Kinetic study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

